Research Paper Volume 11, Issue 11 pp 3561—3573

Downregulation of circ_0132266 in chronic lymphocytic leukemia promoted cell viability through miR-337-3p/PML axis

Wei Wu 1, 2, 3, *, , Zijuan Wu 1, 2, 3, *, , Yi Xia 1, 2, 3, , Shuchao Qin 1, 2, 3, , Yue Li 1, 2, 3, , Jiazhu Wu 1, 2, 3, , Jinhua Liang 1, 2, 3, , Li Wang 1, 2, 3, , Huayuan Zhu 1, 2, 3, , Lei Fan 1, 2, 3, , Jianxin Fu 1, 2, 3, , Wei Xu 1, 2, 3, , Hui Jin 1, 2, 3, , Jianyong Li 1, 2, 3, ,

  • 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China
  • 2 Key Laboratory of Hematology of Nanjing Medical University, Nanjing, 210029, China
  • 3 Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China
* Equal contribution

received: February 1, 2019 ; accepted: May 23, 2019 ; published: June 1, 2019 ;

https://doi.org/10.18632/aging.101997
How to Cite

Copyright: Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Circular RNAs (circRNAs) have recently been reported to play crucial roles in various regulatory processes and involved in cancer onset and progression. However, the potential mechanism of circRNAs in chronic lymphocytic leukemia (CLL) remains largely unknown. Here, we observed hsa_circ_0132266 (circ_0132266), a circRNA significantly decreased in the peripheral blood mononuclear cells (PBMCs) of CLL patients compared with healthy donors, could act as an endogenous sponge of hsa-miR-337-3p (miR-337-3p) and regulate its activity, which resulted in a downstream change of target-gene PML and a consequent influence on cell viability. Taken together, our data indicated the regulatory mechanism of circ_0132266 in CLL progression through circ_0132266/miR-337-3p/PML axis, suggesting that it may serve as a biomarker as well as an exploitable therapeutic target for CLL.

Abbreviations

ceRNA: competitive endogenous RNA; circRNAs: circular RNAs; CLL: chronic lymphocytic leukemia; miRNAs: microRNAs; Mut: mutant; ncRNAs: non-coding RNAs; PAPOLB: poly(A) polymerase beta; PBMC: peripheral blood mononuclear cell; PML: Promyelocytic leukemia protein; WDR26: WD repeat domain 26; WT: wild-type.